Use of Targeted Therapies for Advanced Renal Cell Carcinoma in the Asia-Pacific Region: Opinion Statement From China, Japan, Taiwan, Korea, and Australia
- 5 February 2014
- journal article
- review article
- Published by Elsevier BV in Clinical Genitourinary Cancer
- Vol. 12 (4), 225-233
- https://doi.org/10.1016/j.clgc.2014.01.007
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart reviewInternational Journal of Oncology, 2013
- Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinomaAnti-Cancer Drugs, 2013
- Comparison of PFS and safety for Asian compared to North American and European populations in the phase III trial of pazopanib versus sunitinib in patients with treatment-naive RCC (COMPARZ).Journal of Clinical Oncology, 2013
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals Of Oncology, 2012
- Randomized, Open-Label, Phase III Trial Of Pazopanib Versus Sunitinib In First-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma (MRCC): Results of the Comparz TrialAnnals Of Oncology, 2012
- Sorafenib treatment of Asian patients with advanced renal cell carcinoma (RCC) in daily practice: Subset analysis of the large non-interventional PREDICT study.Journal of Clinical Oncology, 2012
- The Epidemiology of Renal Cell CarcinomaEuropean Urology, 2011
- 7151 POSTER PREDICT (Patient Characteristics in REnal Cell Carcinoma and Daily Practice Treatment With Sorafenib) Non-interventional Study – Final ReportEuropean Journal Of Cancer, 2011
- Epidemiology and risk factors for kidney cancerNature Reviews Urology, 2010
- Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancerBritish Journal of Cancer, 2008